Academia
Sensorium Therapeutics, which closed a $30 million Series A Tuesday, is embracing the complexity of neuropsychiatric diseases with nature-inspired psychoactive medicines.
Working to undo the sins of the past, Colossal Biosciences and the University of Melbourne are attempting to bring back the Tasmanian tiger in a project that could have big implications for human health.
On Nov. 16, the FDA’s Cardiovascular and Renal Drug Advisory Committee will meet to discuss the relative merits of Ardelyx’s tenapanor in chronic kidney disease.
Newly-launched Massachusetts biomanufacturing facility will be something like a conveyor belt from the academic bench to the early startup.
FUJIFILM Dyosynth Biotechnologies, Taysha Gene Therapies, Veravas highlight innovation stemming from the Lone Star state. BioSpace takes a deep dive into these and other Texas innovators.
Recently published research into repairing nerve damage caused by injury may also pay off in treating some of the most vexing neurodegenerative diseases like Alzheimer’s.
Several biotech companies backed by billions are working on different approaches to developing the next big anti-aging therapy - from blood experiments to cell reprogramming.
As a leading biotech hub, the second city still ranks far below many other U.S. locations. That is starting to change, however, as new companies move into the heart of the BioMidwest region.
Neuronal Inflammation was found in two U.S. monkeypox patients, researchers short-list four drugs for potential study in autism and a new test can predict immunotherapy outcomes.
NSCLC At ESMO: Pollution does indeed cause lung cancer; Tecentriq shows promise in poor prognosis patients, Amgen makes progress in KRAS G12-mutated disease and an update on a Daiichi Sankyo ADC.
PRESS RELEASES